Leerink Partners, Piper Sandler, and Cantor Jointly Manage Proposed Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ZURA?
Leerink Partners, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZURA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZURA
Wall Street analysts forecast ZURA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.620
Low
15.00
Averages
16.50
High
18.00
Current: 6.620
Low
15.00
Averages
16.50
High
18.00
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zura Bio to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Zura Bio will participate in the Leerink Global Healthcare Conference on March 10 and the Jefferies Biotech on the Beach Summit on March 11, 2026, where management will meet with investors to enhance engagement and trust.
- Live Webcast Opportunity: The fireside chat at the Leerink Global Healthcare Conference will be available via live webcast on the company's website, with a replay accessible for at least 30 days post-event, ensuring that investors who cannot attend live can still access key information.
- Clinical Research Progress: Zura Bio's lead product candidate, tibulizumab (ZB-106), is undergoing two Phase 2 clinical studies targeting hidradenitis suppurativa and systemic sclerosis, showcasing the company's potential in the autoimmune and inflammatory disease space.
- Multi-Asset Pipeline: In addition to tibulizumab, Zura is evaluating other candidates, including crebankitug (ZB-168) and torudokimab (ZB-880), which have completed Phase 1 studies, indicating the company's strategic positioning to address unmet medical needs.
See More
Zura Bio Completes $144 Million Public Offering
- Offering Size: Zura Bio completed its public offering of 21.2 million Class A ordinary shares at $6.25 per share and 1.8 million pre-funded warrants at $6.249 each on February 26, 2026, raising approximately $144 million, indicating strong market demand for its biopharmaceutical products.
- Underwriter Performance: The offering was managed by Leerink Partners, Piper Sandler, and Cantor, with Wedbush PacGrow as lead manager, reflecting investment banks' confidence in Zura Bio's future growth and laying a foundation for subsequent financing.
- Registration Statement: The offering was conducted under a shelf registration statement on Form S-3, effective as of September 17, 2024, approved by the SEC, ensuring compliance and transparency, which helps enhance investor trust.
- Product Pipeline: Zura Bio's lead candidate tibulizumab (ZB-106) is undergoing two Phase 2 clinical studies targeting refractory autoimmune diseases, demonstrating the company's potential to address unmet medical needs and possibly drive future revenue growth.
See More
Zura Bio Closes $144 Million Public Offering
- Offering Size: Zura Bio completed a public offering of 21.2 million Class A ordinary shares priced at $6.25 each on February 26, 2026, along with 1.8 million pre-funded warrants, indicating strong market demand for its biotech products.
- Funding Amount: The offering generated approximately $144 million in gross proceeds, which will be utilized to support Zura's R&D in autoimmune and inflammatory diseases, thereby advancing its product pipeline.
- Underwriter Lineup: Leerink Partners, Piper Sandler, and Cantor acted as joint bookrunning managers, with Wedbush PacGrow serving as lead manager, reflecting market confidence in Zura and its influence in the biotech sector.
- Pipeline Progress: Zura's lead candidate tibulizumab is currently undergoing two Phase 2 clinical studies targeting difficult-to-treat diseases, further enhancing the company's strategic position in the biopharmaceutical industry.
See More
Zura Bio Prices Public Offering of 18.2 Million Shares
- Offering Size: Zura Bio has announced a public offering of 18.2 million Class A ordinary shares priced at $6.25 per share, with expected gross proceeds of $125 million, indicating strong market demand for its biopharmaceutical products.
- Pre-Funded Warrants: To accommodate certain investors, Zura is also offering pre-funded warrants for 1.8 million Class A ordinary shares at $6.249 each, enhancing investor flexibility and participation in the offering.
- Underwriter Option: Zura has granted underwriters a 30-day option to purchase up to an additional 3 million Class A ordinary shares at the public offering price, a strategy that helps increase market liquidity and attract more investors.
- Closing Date Approaching: The offering is expected to close on February 26, 2026, subject to customary closing conditions, reflecting the company's proactive positioning in the capital markets and its potential for future growth.
See More
Zura Bio Announces Pricing of Public Offering
- Offering Size: Zura Bio announced a public offering of 18,200,000 Class A ordinary shares at $6.25 per share, expecting gross proceeds of $125 million, reflecting the company's strong fundraising capability in the biotechnology sector.
- Pre-Funded Warrants: To cater to specific investor needs, Zura is offering pre-funded warrants for 1,800,000 Class A ordinary shares at $6.249 each, enhancing investor flexibility and participation in the offering.
- Underwriter Option: Zura has granted underwriters a 30-day option to purchase an additional 3,000,000 Class A ordinary shares, a strategy that could provide additional funding support and strengthen its market competitiveness.
- Clinical Research Progress: Zura's lead product candidate, tibulizumab, is undergoing two Phase 2 clinical studies aimed at addressing unmet medical needs in autoimmune and inflammatory diseases, showcasing the company's potential in innovative drug development.
See More
Zura Bio Appoints New Board Members
- Board Changes: Zura Bio announced the appointments of Mark Eisner and Ajay Nirula to its Board of Directors effective February 21, 2026, marking a significant step in advancing the company's clinical development strategy and reflecting confidence in its drug pipeline.
- Rich Industry Experience: Mark Eisner brings over 25 years of leadership in clinical development and immunology, having held executive roles in multiple biotech firms, and is expected to provide valuable guidance for Zura's clinical and regulatory milestones, further propelling the commercialization of its products.
- R&D Leadership: Ajay Nirula has over 20 years of experience in immunology research and clinical development, previously leading several globally approved drug development projects at Eli Lilly, and his addition will enhance Zura's R&D capabilities in autoimmune diseases, supporting the company's dual-pathway antibody strategy.
- Former Board Member Contributions: Neil Graham will step down on the same date, with his contributions during the company's formative stages highly regarded, particularly his involvement in the R&D Committee, highlighting Zura's emphasis on team stability and knowledge transfer.
See More
Zura Bio to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Zura Bio will participate in the Leerink Global Healthcare Conference on March 10 and the Jefferies Biotech on the Beach Summit on March 11, 2026, where management will meet with investors to enhance engagement and trust.
- Live Webcast Opportunity: The fireside chat at the Leerink Global Healthcare Conference will be available via live webcast on the company's website, with a replay accessible for at least 30 days post-event, ensuring that investors who cannot attend live can still access key information.
- Clinical Research Progress: Zura Bio's lead product candidate, tibulizumab (ZB-106), is undergoing two Phase 2 clinical studies targeting hidradenitis suppurativa and systemic sclerosis, showcasing the company's potential in the autoimmune and inflammatory disease space.
- Multi-Asset Pipeline: In addition to tibulizumab, Zura is evaluating other candidates, including crebankitug (ZB-168) and torudokimab (ZB-880), which have completed Phase 1 studies, indicating the company's strategic positioning to address unmet medical needs.
See More
Zura Bio Completes $144 Million Public Offering
- Offering Size: Zura Bio completed its public offering of 21.2 million Class A ordinary shares at $6.25 per share and 1.8 million pre-funded warrants at $6.249 each on February 26, 2026, raising approximately $144 million, indicating strong market demand for its biopharmaceutical products.
- Underwriter Performance: The offering was managed by Leerink Partners, Piper Sandler, and Cantor, with Wedbush PacGrow as lead manager, reflecting investment banks' confidence in Zura Bio's future growth and laying a foundation for subsequent financing.
- Registration Statement: The offering was conducted under a shelf registration statement on Form S-3, effective as of September 17, 2024, approved by the SEC, ensuring compliance and transparency, which helps enhance investor trust.
- Product Pipeline: Zura Bio's lead candidate tibulizumab (ZB-106) is undergoing two Phase 2 clinical studies targeting refractory autoimmune diseases, demonstrating the company's potential to address unmet medical needs and possibly drive future revenue growth.
See More
Zura Bio Closes $144 Million Public Offering
- Offering Size: Zura Bio completed a public offering of 21.2 million Class A ordinary shares priced at $6.25 each on February 26, 2026, along with 1.8 million pre-funded warrants, indicating strong market demand for its biotech products.
- Funding Amount: The offering generated approximately $144 million in gross proceeds, which will be utilized to support Zura's R&D in autoimmune and inflammatory diseases, thereby advancing its product pipeline.
- Underwriter Lineup: Leerink Partners, Piper Sandler, and Cantor acted as joint bookrunning managers, with Wedbush PacGrow serving as lead manager, reflecting market confidence in Zura and its influence in the biotech sector.
- Pipeline Progress: Zura's lead candidate tibulizumab is currently undergoing two Phase 2 clinical studies targeting difficult-to-treat diseases, further enhancing the company's strategic position in the biopharmaceutical industry.
See More
Zura Bio Prices Public Offering of 18.2 Million Shares
- Offering Size: Zura Bio has announced a public offering of 18.2 million Class A ordinary shares priced at $6.25 per share, with expected gross proceeds of $125 million, indicating strong market demand for its biopharmaceutical products.
- Pre-Funded Warrants: To accommodate certain investors, Zura is also offering pre-funded warrants for 1.8 million Class A ordinary shares at $6.249 each, enhancing investor flexibility and participation in the offering.
- Underwriter Option: Zura has granted underwriters a 30-day option to purchase up to an additional 3 million Class A ordinary shares at the public offering price, a strategy that helps increase market liquidity and attract more investors.
- Closing Date Approaching: The offering is expected to close on February 26, 2026, subject to customary closing conditions, reflecting the company's proactive positioning in the capital markets and its potential for future growth.
See More
Zura Bio Announces Pricing of Public Offering
- Offering Size: Zura Bio announced a public offering of 18,200,000 Class A ordinary shares at $6.25 per share, expecting gross proceeds of $125 million, reflecting the company's strong fundraising capability in the biotechnology sector.
- Pre-Funded Warrants: To cater to specific investor needs, Zura is offering pre-funded warrants for 1,800,000 Class A ordinary shares at $6.249 each, enhancing investor flexibility and participation in the offering.
- Underwriter Option: Zura has granted underwriters a 30-day option to purchase an additional 3,000,000 Class A ordinary shares, a strategy that could provide additional funding support and strengthen its market competitiveness.
- Clinical Research Progress: Zura's lead product candidate, tibulizumab, is undergoing two Phase 2 clinical studies aimed at addressing unmet medical needs in autoimmune and inflammatory diseases, showcasing the company's potential in innovative drug development.
See More
Zura Bio Appoints New Board Members
- Board Changes: Zura Bio announced the appointments of Mark Eisner and Ajay Nirula to its Board of Directors effective February 21, 2026, marking a significant step in advancing the company's clinical development strategy and reflecting confidence in its drug pipeline.
- Rich Industry Experience: Mark Eisner brings over 25 years of leadership in clinical development and immunology, having held executive roles in multiple biotech firms, and is expected to provide valuable guidance for Zura's clinical and regulatory milestones, further propelling the commercialization of its products.
- R&D Leadership: Ajay Nirula has over 20 years of experience in immunology research and clinical development, previously leading several globally approved drug development projects at Eli Lilly, and his addition will enhance Zura's R&D capabilities in autoimmune diseases, supporting the company's dual-pathway antibody strategy.
- Former Board Member Contributions: Neil Graham will step down on the same date, with his contributions during the company's formative stages highly regarded, particularly his involvement in the R&D Committee, highlighting Zura's emphasis on team stability and knowledge transfer.
See More
